布隆妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | Notch 1 |
| 臨床資料 | |
| 其他名稱 | OMP-52M51 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1447814-75-6 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6392H9862N1980O1710S50 |
| 摩尔质量 | 143,410.36 g·mol−1 |
布隆妥珠单抗（INN：brontictuzumab；开发代号：OMP-52M51）是一种人源化单克隆抗体，设计用于治疗癌症。[1][2]该药物靶向Notch1并抑制通路激活。[3]
该药物由OncoMed开发。
参考资料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2) [2024-03-06]. （原始内容存档 (PDF)于2020-08-15）.
- ^ Ferrarotto, R.; Eckhardt, G.; Patnaik, A.; LoRusso, P.; Faoro, L.; Heymach, J. V.; Kapoun, A. M.; Xu, L.; Munster, P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018-07-01, 29 (7) [2024-03-06]. ISSN 1569-8041. PMID 29726923. doi:10.1093/annonc/mdy171. （原始内容存档于2024-05-31）.